REGN•benzinga•
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
Summary
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga